Looming Launches Predicted To Offset Lupin Pressures
Metformin Recalls And Oseltamivir Write-offs Caused Trouble For The Indian Firm
Lupin delivered a shaky Q3 as profit margins fell following complications with metformin and oseltamivir, but the firm appears confident that several impending high-value launches will set it back on the right track.
